Pub Date : 2024-05-01Epub Date: 2023-07-11DOI: 10.1089/derm.2023.0098
Lucía García Sirvent, Alberto Antonio González Ruiz, Pedro Gil Pallares, Alba Navarro Bielsa, Joaquín Espiñeira Sicre, Juan Francisco Silvestre Salvador
{"title":"Pityriasis Versicolor in Dupilumab-Treated Atopic Dermatitis® Patients: A Possible Underestimated Side Effect.","authors":"Lucía García Sirvent, Alberto Antonio González Ruiz, Pedro Gil Pallares, Alba Navarro Bielsa, Joaquín Espiñeira Sicre, Juan Francisco Silvestre Salvador","doi":"10.1089/derm.2023.0098","DOIUrl":"10.1089/derm.2023.0098","url":null,"abstract":"","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"307-308"},"PeriodicalIF":4.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9767031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01Epub Date: 2023-09-11DOI: 10.1089/derm.2023.0176
Trinidad Montero-Vilchez, Juan-Angel Rodriguez-Pozo, Carlos Cuenca-Barrales, Raquel Sanabria-de-la-Torre, Jesus-Manuel Torres-de-Pinedo, Salvador Arias-Santiago
Background: Dupilumab is an effective treatment for atopic Dermatitis® (AD) and it also restores skin barrier function. Nevertheless, early changes in epidermal barrier parameters related to sustained treatment response or treatment failure are not known. So, the objective of this study is to evaluate whether changes in skin barrier function after 16 weeks dupilumab treatment could predict sustained treatment response or treatment failure. Materials and Methods: A prospective observational study was conducted that included patients with AD starting dupilumab. Clinical scores, patient-reported outcome measures (PROMs), and skin barrier function parameters were assessed at baseline and after 16 weeks treatment. Patients were followed until they failed to dupilumab or until the end of the study period. Participants were divided into 2 groups: patients with treatment failure and those with sustained treatment response. Results: In total, 32 patients with AD were included in the study, with a mean age of 28.03 years (standard deviation 10.65), being 20 (60.6%) females. In total, 22 (66.7%) patients sustained dupilumab response during the study period and only 10 (33.3%) failed to treatment. After 16 weeks treatment, clinical scores were improved in both groups. Patients with sustained treatment response increased stratum corneum hydration (SCH) on noninvolved skin (34.25 arbitrary units [AU] vs 44.90AU, P = 0.001) and on eczematous lesions (20.71 AU vs 40.94 AU, P < 0.001) and also decreased transepidermal water loss (TEWL) on eczematous lesions (28.22 g/[m2·h] vs 14.83 g/[m2·h], P = 0.002). Patients with treatment failure did not change TEWL or SCH. SCH after 16 weeks treatment on noninvolved skin (odds ratio [OR] = 0.83, P = 0.018) and SCH after 16 weeks treatment on eczematous lesions (OR = 0.86, P = 0.028) were related to dupilumab failure. Conclusion: SCH could be used as a predictive biomarker of dupilumab response in patients with AD.
背景介绍杜比鲁单抗是治疗特应性皮炎®（AD）的有效药物，它还能恢复皮肤屏障功能。然而，与持续治疗反应或治疗失败相关的表皮屏障参数的早期变化尚不清楚。因此，本研究的目的是评估杜比鲁单抗治疗 16 周后皮肤屏障功能的变化能否预测持续治疗反应或治疗失败。材料与方法：本研究是一项前瞻性观察研究，纳入了开始使用杜必鲁单抗的 AD 患者。在基线和治疗 16 周后对临床评分、患者报告的结果测量（PROMs）和皮肤屏障功能参数进行评估。对患者进行随访，直到他们对杜比鲁单抗无效或研究期结束。参与者分为两组：治疗失败的患者和治疗反应持续的患者。研究结果共有32名AD患者参与研究，平均年龄为28.03岁（标准差10.65），其中女性20人（60.6%）。在研究期间，共有22名（66.7%）患者对杜比鲁单抗产生了反应，只有10名（33.3%）患者治疗失败。治疗 16 周后，两组患者的临床评分均有所改善。治疗反应持续的患者非受累皮肤的角质层水合作用（SCH）增加（34.25 任意单位 [AU] vs 44.90AU，P = 0.001），湿疹皮损的角质层水合作用（20.71 AU vs 40.94 AU，P 2-h] vs 14.83 g/[m2-h]，P = 0.002）也增加。治疗失败的患者的 TEWL 和 SCH 没有变化。非受累皮肤治疗16周后的SCH（几率比[OR] = 0.83，P = 0.018）和湿疹皮损治疗16周后的SCH（OR = 0.86，P = 0.028）与dupilumab治疗失败有关。结论SCH可作为杜必鲁单抗对AD患者反应的预测性生物标志物。
{"title":"Stratum Corneum Hydration As a Potential Marker of Response to Dupilumab in Atopic Dermatitis®: A Prospective Observational Study.","authors":"Trinidad Montero-Vilchez, Juan-Angel Rodriguez-Pozo, Carlos Cuenca-Barrales, Raquel Sanabria-de-la-Torre, Jesus-Manuel Torres-de-Pinedo, Salvador Arias-Santiago","doi":"10.1089/derm.2023.0176","DOIUrl":"10.1089/derm.2023.0176","url":null,"abstract":"<p><p><u><b><i>Background</i></b><i>:</i></u> Dupilumab is an effective treatment for atopic Dermatitis® (AD) and it also restores skin barrier function. Nevertheless, early changes in epidermal barrier parameters related to sustained treatment response or treatment failure are not known. So, the objective of this study is to evaluate whether changes in skin barrier function after 16 weeks dupilumab treatment could predict sustained treatment response or treatment failure. <u><b><i>Materials and Methods</i></b></u><i>:</i> A prospective observational study was conducted that included patients with AD starting dupilumab. Clinical scores, patient-reported outcome measures (PROMs), and skin barrier function parameters were assessed at baseline and after 16 weeks treatment. Patients were followed until they failed to dupilumab or until the end of the study period. Participants were divided into 2 groups: patients with treatment failure and those with sustained treatment response. <u><b><i>Results:</i></b></u> In total, 32 patients with AD were included in the study, with a mean age of 28.03 years (standard deviation 10.65), being 20 (60.6%) females. In total, 22 (66.7%) patients sustained dupilumab response during the study period and only 10 (33.3%) failed to treatment. After 16 weeks treatment, clinical scores were improved in both groups. Patients with sustained treatment response increased stratum corneum hydration (SCH) on noninvolved skin (34.25 arbitrary units [AU] vs 44.90AU, <i>P</i> = 0.001) and on eczematous lesions (20.71 AU vs 40.94 AU, <i>P</i> < 0.001) and also decreased transepidermal water loss (TEWL) on eczematous lesions (28.22 g/[m<sup>2</sup>·h] vs 14.83 g/[m<sup>2</sup>·h], <i>P</i> = 0.002). Patients with treatment failure did not change TEWL or SCH. SCH after 16 weeks treatment on noninvolved skin (odds ratio [OR] = 0.83, <i>P</i> = 0.018) and SCH after 16 weeks treatment on eczematous lesions (OR = 0.86, <i>P</i> = 0.028) were related to dupilumab failure. <u><b><i>Conclusion</i></b><i>:</i></u> SCH could be used as a predictive biomarker of dupilumab response in patients with AD.</p>","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"250-257"},"PeriodicalIF":4.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10212852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Filomena Russo, Vittoria Cioppa, Laura Lazzeri, Nicola Milanesi, Marco Galluzzo, Angelo Massimiliano D'Erme, Natale Schettini, Barbara Cocuroccia, Donatella Sordi, Annarita Panebianco, Marina Talamonti, Claudia Paganini, Ornella De Pità, Anna Rita Giampetruzzi, Giovanni Luca Scaglione
Background and Objective: Atopic Dermatitis (AD) is the most prevalent inflammatory skin disorder resulting in an intense impact on patients quality of life. The aim of this study is to evaluate the clinical meaning of the DLQI scores documented between different phenotypes of AD patients under biologic therapy with Dupilumab. Method: We conducted a retrospective analysis of 209 patients with AD treated with Dupilumab for 2 years. These patients were categorized into different clinical phenotypes. Severity of the disease was assessed by using the Eczema Area and Severity Index (EASI), Numerical Scale Rating (NRS) for sleep (NRS sleep), pruritus (NRS pruritus) and Dermatology Life Quality Index (DLQI) at baseline and subsequently at 4,12 and 24 months. Results: Our results show that the higher DLQI scores (mean: 18.6, range:9-30) achieved at T0 are associated with a prurigo nodularis AD pattern, while after 24 months (T3) of therapy with Dupilumab, the worst quality of life index results were reported in Flexural and Head-Neck combined clinical phenotypes. Conclusions: Quality of life is probably what matters most as an overall endpoint in AD. Assessing the clinical meaning of DLQI scores across different AD phenotypes could be a further aid when considering decision making factors in patient management.
{"title":"Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab.","authors":"Filomena Russo, Vittoria Cioppa, Laura Lazzeri, Nicola Milanesi, Marco Galluzzo, Angelo Massimiliano D'Erme, Natale Schettini, Barbara Cocuroccia, Donatella Sordi, Annarita Panebianco, Marina Talamonti, Claudia Paganini, Ornella De Pità, Anna Rita Giampetruzzi, Giovanni Luca Scaglione","doi":"10.1089/derm.2023.0357","DOIUrl":"https://doi.org/10.1089/derm.2023.0357","url":null,"abstract":"<b><i><u>Background and Objective:</u></i></b> Atopic Dermatitis (AD) is the most prevalent inflammatory skin disorder resulting in an intense impact on patients quality of life. The aim of this study is to evaluate the clinical meaning of the DLQI scores documented between different phenotypes of AD patients under biologic therapy with Dupilumab. <u><b><i>Method:</i></b></u> We conducted a retrospective analysis of 209 patients with AD treated with Dupilumab for 2 years. These patients were categorized into different clinical phenotypes. Severity of the disease was assessed by using the Eczema Area and Severity Index (EASI), Numerical Scale Rating (NRS) for sleep (NRS sleep), pruritus (NRS pruritus) and Dermatology Life Quality Index (DLQI) at baseline and subsequently at 4,12 and 24 months. <u><b><i>Results:</i></b></u> Our results show that the higher DLQI scores (mean: 18.6, range:9-30) achieved at T0 are associated with a prurigo nodularis AD pattern, while after 24 months (T3) of therapy with Dupilumab, the worst quality of life index results were reported in Flexural and Head-Neck combined clinical phenotypes. <u><b><i>Conclusions:</i></b></u> Quality of life is probably what matters most as an overall endpoint in AD. Assessing the clinical meaning of DLQI scores across different AD phenotypes could be a further aid when considering decision making factors in patient management.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":"27 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140799210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ketamine, dimethyltryptamine, DMT, phencyclidine, PCP, dextromethorphan, psilocybin, and ayahuasca), and dermatosis terms (dermatitis, contact dermatitis, drug eruption, skin reaction, and urticaria). Studies were included if there was an association with a psychedelic or hallucinogenic and any cutaneous reaction; studies without both components were excluded. Twenty-two studies met inclusion criteria, describing reactions to cannabis (10 studies), MDMA (5 studies), ketamine (4 studies), and psilocybin (3 studies). Forty total patients were included. Among cannabis-related reactions, the most common reaction was type I hypersensitivity by topical exposure (n = 21). Three patients reported type IV hypersensitivity reactions to contact with cannabis or cannabis-derived oils, all of whom experienced vesicular contact dermatitis. Two additional patients presented with an erythema-multiforme-like reaction and acute generalized exanthematous pustulosis after systemic administration, respectively. MDMA was associated with acneiform eruptions (2 cases), an urticarial eruption, a guttate psoriasis-like reaction, a fixed drug eruption, and Stevens-Johnson syndrome (1 case). Four patients reported type I hypersensitivity reactions to ketamine. Four patients reported vesicular eruptions, cyanosis, or widespread jaundice to psilocybin. Of the cases, 8 patients had cutaneous reactions that resolved with drug cessation, 10 resolved with cessation plus treatment, and resolution in 7 cases was not reported. Zero studies were found describing other psychedelic or hallucinogenic compounds. Further research is required to characterize reactions and treatments linked to the variety of extant psychedelics and hallucinogens.
{"title":"Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens.","authors":"Syed Minhaj Rahman, Yousef Salem, Aamir Hussain","doi":"10.1089/derm.2023.0292","DOIUrl":"https://doi.org/10.1089/derm.2023.0292","url":null,"abstract":"<u><b><i/></b></u>Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ketamine, dimethyltryptamine, DMT, phencyclidine, PCP, dextromethorphan, psilocybin, and ayahuasca), and dermatosis terms (dermatitis, contact dermatitis, drug eruption, skin reaction, and urticaria). Studies were included if there was an association with a psychedelic or hallucinogenic and any cutaneous reaction; studies without both components were excluded. Twenty-two studies met inclusion criteria, describing reactions to cannabis (10 studies), MDMA (5 studies), ketamine (4 studies), and psilocybin (3 studies). Forty total patients were included. Among cannabis-related reactions, the most common reaction was type I hypersensitivity by topical exposure (n = 21). Three patients reported type IV hypersensitivity reactions to contact with cannabis or cannabis-derived oils, all of whom experienced vesicular contact dermatitis. Two additional patients presented with an erythema-multiforme-like reaction and acute generalized exanthematous pustulosis after systemic administration, respectively. MDMA was associated with acneiform eruptions (2 cases), an urticarial eruption, a guttate psoriasis-like reaction, a fixed drug eruption, and Stevens-Johnson syndrome (1 case). Four patients reported type I hypersensitivity reactions to ketamine. Four patients reported vesicular eruptions, cyanosis, or widespread jaundice to psilocybin. Of the cases, 8 patients had cutaneous reactions that resolved with drug cessation, 10 resolved with cessation plus treatment, and resolution in 7 cases was not reported. Zero studies were found describing other psychedelic or hallucinogenic compounds. Further research is required to characterize reactions and treatments linked to the variety of extant psychedelics and hallucinogens.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":"192 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140628543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease. However, few studies have investigated brain changes associated with chronic inflammation. We hypothesized that chronic inflammation might be related to brain structural alterations in patients with AD. Objectives: To investigate the association between disease severity (Eczema Area and Severity Index [EASI]), proinflammatory cytokines, and differences in brain gray matter (GM) volume in patients with AD. Methods: Nineteen patients with AD and 19 age- and sex-matched healthy subjects were enrolled. All participants underwent clinical assessment and brain magnetic resonance imaging. Voxel-based morphometry was performed to analyze GM volume differences. Results: Patients with AD exhibited significantly decreased GM volume in many brain regions, such as bilateral precentral gyrus, right frontal pole, and right middle temporal gyrus (P < 0.001), compared with healthy subjects. Notably, in patients with AD, the GM volume in right middle temporal gyrus was negatively associated with both EASI score and proinflammatory cytokines (sIL-2R [soluble interleukin 2 receptor] and TNF-α receptor-1), whereas the GM volume in left precentral gyrus was negatively associated with both EASI score and proinflammatory cytokines (sIL-2R and CRP). Conclusion: Patients with AD demonstrated significant brain GM volume reduction in many brain regions, which is related to disease severity and proinflammatory cytokines.
背景：特应性皮炎（AD）是一种慢性炎症性皮肤病：特应性皮炎（AD）是一种慢性炎症性皮肤病。然而，很少有研究调查与慢性炎症相关的大脑变化。我们假设慢性炎症可能与 AD 患者的大脑结构改变有关。研究目的研究 AD 患者的疾病严重程度（湿疹面积和严重程度指数 [EASI]）、促炎细胞因子与脑灰质（GM）体积差异之间的关联。研究方法招募 19 名 AD 患者和 19 名年龄与性别匹配的健康受试者。所有参与者均接受了临床评估和脑磁共振成像检查。采用基于体素的形态计量学方法分析大脑灰质体积的差异。结果显示与健康受试者相比，AD 患者的许多脑区，如双侧中央前回、右额极和右颞中回的 GM 体积明显减少（P < 0.001）。值得注意的是，在 AD 患者中，右颞中回的 GM 体积与 EASI 评分和促炎细胞因子（sIL-2R [可溶性白细胞介素 2 受体] 和 TNF-α 受体-1）均呈负相关，而左侧中央前回的 GM 体积与 EASI 评分和促炎细胞因子（sIL-2R 和 CRP）均呈负相关。结论AD患者多个脑区的脑基因组体积明显缩小，这与疾病严重程度和促炎细胞因子有关。
{"title":"Correlation of Disease Severity, Proinflammatory Cytokines, and Reduced Brain Gray Matter Volumes in Patients with Atopic Dermatitis.","authors":"Cheng-Yuan Li, Wan-Chen Chang, Mu-Hong Chen, Pei-Chi Tu, Tai-Li Chen, Chih-Chiang Chen, Yun-Ting Chang, You-Yin Chen, Ya-Mei Bai","doi":"10.1089/derm.2023.0340","DOIUrl":"https://doi.org/10.1089/derm.2023.0340","url":null,"abstract":"<u><b><i>Background:</i></b></u> Atopic dermatitis (AD) is a chronic inflammatory skin disease. However, few studies have investigated brain changes associated with chronic inflammation. We hypothesized that chronic inflammation might be related to brain structural alterations in patients with AD. <u><b><i>Objectives:</i></b></u> To investigate the association between disease severity (Eczema Area and Severity Index [EASI]), proinflammatory cytokines, and differences in brain gray matter (GM) volume in patients with AD. <u><b><i>Methods:</i></b></u> Nineteen patients with AD and 19 age- and sex-matched healthy subjects were enrolled. All participants underwent clinical assessment and brain magnetic resonance imaging. Voxel-based morphometry was performed to analyze GM volume differences. <u><b><i>Results:</i></b></u> Patients with AD exhibited significantly decreased GM volume in many brain regions, such as bilateral precentral gyrus, right frontal pole, and right middle temporal gyrus (<i>P</i> < 0.001), compared with healthy subjects. Notably, in patients with AD, the GM volume in right middle temporal gyrus was negatively associated with both EASI score and proinflammatory cytokines (sIL-2R [soluble interleukin 2 receptor] and TNF-α receptor-1), whereas the GM volume in left precentral gyrus was negatively associated with both EASI score and proinflammatory cytokines (sIL-2R and CRP). <u><b><i>Conclusion:</i></b></u> Patients with AD demonstrated significant brain GM volume reduction in many brain regions, which is related to disease severity and proinflammatory cytokines.","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":"127 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140628414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01Epub Date: 2023-07-20DOI: 10.1089/derm.2023.0146
Blake Van Noord, Christen Samaan, Alexandra Flamm
{"title":"A Case of Delayed and Immediate Hypersensitivity Reactions Induced by Corticosteroids.","authors":"Blake Van Noord, Christen Samaan, Alexandra Flamm","doi":"10.1089/derm.2023.0146","DOIUrl":"10.1089/derm.2023.0146","url":null,"abstract":"","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"191-192"},"PeriodicalIF":5.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9842928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prayer rituals are an integral part of the daily lives of Muslims worldwide. This comprehensive review aims to explore the common dermatoses associated with prayer among Muslims and provide insights for dermatologists to facilitate accurate diagnosis and reduce unnecessary investigations. A systematic literature search returned 367 published articles, of which 21 met the inclusion criteria. Friction-induced dermatitis was the most frequently reported dermatosis, primarily affecting the forehead, knees, dorsum of the feet, and lateral malleoli. Friction-related marks often present as hyperpigmented lichenified plaques, and are more common in elderly individuals and males. Cases of contact dermatitis and fungal infections were also reported. Allergic contact dermatitis was linked to perfume application before Friday prayers, whereas fungal infections were attributed to increased water retention between toe webs, possibly related to communal ablution and prayer areas. Awareness of these prayer-related dermatoses enables dermatologists to provide holistic care for diverse populations and targeting specific interventions with respect for patients' religious beliefs. For example, Muslim patients with symptomatic frictional dermatoses may benefit from use of padded prayer rugs, especially diabetic patients whose lesions carry an increased risk of progressing to neuropathic ulcers.
{"title":"Prayer-Related Dermatoses in Muslims.","authors":"Yousef Salem, Syed Minhaj Rahman, Mojahed Shalabi, Aamir Hussain","doi":"10.1089/derm.2023.0191","DOIUrl":"10.1089/derm.2023.0191","url":null,"abstract":"<p><p><u><b><i></i></b></u> Prayer rituals are an integral part of the daily lives of Muslims worldwide. This comprehensive review aims to explore the common dermatoses associated with prayer among Muslims and provide insights for dermatologists to facilitate accurate diagnosis and reduce unnecessary investigations. A systematic literature search returned 367 published articles, of which 21 met the inclusion criteria. Friction-induced dermatitis was the most frequently reported dermatosis, primarily affecting the forehead, knees, dorsum of the feet, and lateral malleoli. Friction-related marks often present as hyperpigmented lichenified plaques, and are more common in elderly individuals and males. Cases of contact dermatitis and fungal infections were also reported. Allergic contact dermatitis was linked to perfume application before Friday prayers, whereas fungal infections were attributed to increased water retention between toe webs, possibly related to communal ablution and prayer areas. Awareness of these prayer-related dermatoses enables dermatologists to provide holistic care for diverse populations and targeting specific interventions with respect for patients' religious beliefs. For example, Muslim patients with symptomatic frictional dermatoses may benefit from use of padded prayer rugs, especially diabetic patients whose lesions carry an increased risk of progressing to neuropathic ulcers.</p>","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"132-137"},"PeriodicalIF":4.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10128849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01Epub Date: 2023-08-22DOI: 10.1089/derm.2023.0120
Aishwarya Sharma, Aman Sandhu
{"title":"A Case of Morphea After COVID-19 Vaccination.","authors":"Aishwarya Sharma, Aman Sandhu","doi":"10.1089/derm.2023.0120","DOIUrl":"10.1089/derm.2023.0120","url":null,"abstract":"","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"187-188"},"PeriodicalIF":5.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-01Epub Date: 2023-08-17DOI: 10.1089/derm.2023.0143
Samuel F Ekstein, Nicholas Battis, Dominick Dabrowski, Anne B Neeley
Background: Propylene glycol (PG) and butylene glycol (BG) are not known to be cross-reactors. However, no large-scale studies have assessed the cross-reactivity rate (CRR) between these 2 structurally and functionally similar compounds. Objectives: The aim of this study was to determine whether PG and BG demonstrate cross-reactivity. Methods: This is a retrospective chart review of 893 patients who underwent patch testing for both PG and BG from 2020 to 2022. The frequencies of positive reactions and concomitant reaction rates were calculated. Results: In our cohort, 53 (5.94%) patients reacted to PG and 13 patients (1.46%) reacted to BG. Of the patients who reacted to PG, 6 reacted to BG representing a CRR of 11.3%, whereas the CRR to PG in BG-allergic patients was 46.2%. Conclusions: For those allergic to BG, PG should be considered a cross-reactor. This relationship is somewhat unidirectional, as patients allergic to PG demonstrated a CRR to BG of only 11.3%, significantly lower than the 46.2% CRR to PG among BG-allergic patients.
{"title":"Cross-Reactivity Between Propylene Glycol and Butylene Glycol.","authors":"Samuel F Ekstein, Nicholas Battis, Dominick Dabrowski, Anne B Neeley","doi":"10.1089/derm.2023.0143","DOIUrl":"10.1089/derm.2023.0143","url":null,"abstract":"<p><p><u><b><i>Background:</i></b></u> Propylene glycol (PG) and butylene glycol (BG) are not known to be cross-reactors. However, no large-scale studies have assessed the cross-reactivity rate (CRR) between these 2 structurally and functionally similar compounds. <u><b><i>Objectives</i></b><i>:</i></u> The aim of this study was to determine whether PG and BG demonstrate cross-reactivity. <u><b><i>Methods:</i></b></u> This is a retrospective chart review of 893 patients who underwent patch testing for both PG and BG from 2020 to 2022. The frequencies of positive reactions and concomitant reaction rates were calculated. <u><b><i>Results:</i></b></u> In our cohort, 53 (5.94%) patients reacted to PG and 13 patients (1.46%) reacted to BG. Of the patients who reacted to PG, 6 reacted to BG representing a CRR of 11.3%, whereas the CRR to PG in BG-allergic patients was 46.2%. <u><b><i>Conclusions:</i></b></u> For those allergic to BG, PG should be considered a cross-reactor. This relationship is somewhat unidirectional, as patients allergic to PG demonstrated a CRR to BG of only 11.3%, significantly lower than the 46.2% CRR to PG among BG-allergic patients.</p>","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"149-151"},"PeriodicalIF":5.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10018182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号